Cytokinetics Inc. Stock
Cytokinetics Inc. Stock
We can see a decrease in the price for Cytokinetics Inc.. Compared to yesterday it has lost -€1.620 (-2.320%).
With 41 Buy predictions and not a single Sell prediction Cytokinetics Inc. is an absolute favorite of our community.
With a target price of 81 € there is a slightly positive potential of 18.87% for Cytokinetics Inc. compared to the current price of 68.14 €.
So far the community has only identified positive things for Cytokinetics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -2.320% | -3.165% | -6.463% | 119.371% | 30.393% | 135.676% | 183.577% |
| Evolus Inc | -0.040% | -0.954% | -14.526% | -33.462% | -4.771% | -42.967% | -41.356% |
| Heron Therapeutics Inc. | 1.530% | 3.155% | 15.773% | -72.386% | -61.257% | -69.171% | -95.838% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
Cytokinetics (CYTK) was upgraded by UBS Group AG from "neutral" to "buy".
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its price target raised by Mizuho from $100.00 to $118.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for CYTK provided by MarketBeat
News
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
Robert I. Blum, president & CEO of Cytokinetics, Incorporated (NASDAQ:CYTK), reported a sale of 7,500 shares of common stock on July 13, 2026, according to an SEC Form 4 filing.
Transaction value
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYKORZO’s launch is outperforming expectations, with Cytokinetics saying early prescriptions
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
On Feb. 5, 2026, Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics (NASDAQ:CYTK), exercised 15,000 options for common stock and immediately sold the resulting